Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind Phase 2 trial of MABT5102A in Alzheimer's disease
2010-022598-32Phase 2Completed
- Sponsor
- Genentech
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing MABT5102A with Placebo (2 arms). Primary endpoint: Change in brain amyloid load. Started Nov 2011; status: completed.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2010-022598-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022598-32.